Brentuximab vedotin Antibody
Brentuximab vedotin (SGN-35) is an antibody-drug conjugate (ADC) designed to target CD30, delivering the cytotoxic agent monomethyl auristatin E to disrupt microtubules in lymphoma cells. It is widely used in preclinical research for studying Hodgkin lymphoma and systemic anaplastic large cell lymphoma, supporting both in vitro cytotoxicity assays and in vivo xenograft model experiments.
Product Specifications
Product Name Alternative
SGN-35, Antibody-Drug Conjugates, AntibodyDrug Conjugates (ADCs), AntibodyDrugConjugates (ADCs), AntibodyDrugConjugates, ADCs, ADC linker
Target
Antibody-Drug Conjugates (ADCs)
Clonality
Monoclonal
Conjugation
Unconjugated
Concentration
9.36 mg/mL
Purity
95.00% (May vary between batches)
Molecular Weight
150.23 kDa
Storage Conditions
Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Notes
For research use only.
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
MUC1 / EMA / CD227 (Epithelial Marker) (rMUC1/960), CF640R conjugate, 0.1mg/mL
